Niewinski and colleagues aimed to assess real-world use of daratumumab for patients with multiple myeloma and renal insufficiency. They performed a retrospective chart review of 101 patients ...

12 On the basis of these findings, daratumumab monotherapy at a dose of 16 mg per kilogram of body weight was approved by the Food and Drug Administration for the treatment of multiple myeloma in ...

Patients in the daratumumab group received intravenous daratumumab at a dose of 16 mg per kilogram of body weight once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6 ...

Evaluated doses — based on the approved weekly 16-mg/kg IV dose for daratumumab — were 1,200 mg (n = 8; median age, 65.5 years) or 1,800 mg (n = 45; median age, 63 years). Treatment was ...

following the first dose of daratumumab. The cells remained depleted throughout the course of treatment with daratumumab, suggesting that the drug can dampen the immunosuppressive effects of Tregs.

Treatment discontinuation due to a TEAE occurred in 5.7% of patients on daratumumab. Dose modifications were required for 46.6% of patients. Based on an earlier assessment of AQUILA, the developer ...

Daratumumab dosing was 1800 mg, with pomalidomide 2 mg, starting at cycle 2. 1,4 Results as of April 10, 2024, showed the following: 4 77 patients received the triplet of talquetamab, daratumumab ...

The patient received daratumumab infusions at a dosage of 16 mg/kg once a week. The drug was added to oral cyclophosphamide, prednisolone, and avacopan. Eleven days following receipt of daratumuma ...

Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ...

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...